MetaVia Inc.
MTVA evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $10.9M
- Lead Asset:
- da-1241 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for MTVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MTVA
MetaVia Inc. (MTVA) is a clinical-stage biotechnology company developing novel therapeutics for cardiometabolic diseases, with lead programs in MASH and obesity.
Key risk: Funding risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$10.9M
Cash Runway
—
Lead Asset
da-1241 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for MetaVia Inc..
MetaVia Inc. (MTVA) is a clinical-stage biotechnology company developing novel therapeutics for cardiometabolic diseases, with lead programs in MASH and obesity.
- Cash & equivalents of $12.6M as of 2026-06-30 [sec].
- Net income of -$5.3M as of 2026-06-30 [sec].
- Shareholders' equity of $6.8M as of 2026-06-30 [sec].
- Lead candidate DA-1726 (dual GLP1R/GCGR agonist) is in Phase 1 clinical trials for obesity, with positive 8-week 48 mg cohort results announced January 2026 [news · 2026-01-21].
- Vanoglipel (DA-1241) is in a Phase 2a trial for MASH, with a completed study and CSR being finalized [sec · filed 2026-01-05].
What works
- DA-1726 has shown statistically significant weight loss in the 48 mg cohort of its Phase 1b trial, supporting further development [news · 2026-01-21].
- The company has strengthened its intellectual property for DA-1726 with 39 granted and pending patents providing protection at least through 2041 [sec_mda · as of 2026-03-26].
- Preclinical data for DA-1241 demonstrated additive hepatoprotective effects in combination with Efruxifermin in a MASH mouse model [sec_mda · as of 2025-08-07].
What to weigh
- The company has a net loss of $5.3M as of 2026-06-30 and faces significant risks in securing additional funding before achieving sustainable revenues [sec · filed 2026-01-12].
- MetaVia has several legacy programs (ANA001, NB-01, NB-02, Gemcabene) that it is not planning to advance and is seeking out-licensing or divestiture opportunities [sec · filed 2026-01-05].
- The company acknowledges that its drug discovery efforts may not succeed and that drug candidates may not begin clinical trials [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
Positive Phase 1b results for DA-1726 48 mg cohort
“positive and statistically significant results from the 8-week 48 mg cohort from the Phase 1b trial of DA-1726”
News · January 21, 2026
DA-1726 patent protection
“39 granted and pending patents in the U.S. and internationally, providing protection at least through 2041”
SEC MD&A · March 26, 2026
Risks & what to watch (3)›
Key risks
- Funding risk — The company may fail to secure additional funding before achieving sustainable revenues and profit [sec · filed 2026-01-12].
- Clinical trial failure — Drug candidates may not succeed or may not begin clinical trials [sec_mda · as of 2026-03-26].
- Legacy program divestiture — Several programs are being out-licensed or divested, indicating potential resource constraints [sec · filed 2026-01-05].
What to watch
- Initiation of Phase 1 Part 3 titration study of DA-1726 in April 2026 [news · 2026-03-31].
- Data readout for Phase 1 Part 3a and Part 3b of DA-1726 planned for Q4 2026 [sec · filed 2026-01-12].
- Finalization of the CSR for the Phase 2a MASH trial of vanoglipel (DA-1241) [sec · filed 2026-01-05].
Sources: News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run MetaVia Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MetaVia Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.95 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$80K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 33,635 | $40K |
| jane street group, llc | 10,903 | $13K |
| aries wealth management | 10,000 | $12K |
| vanguard fiduciary trust co | 6,940 | $8K |
| tower research capital llc (trc) | 2,602 | $3K |
| vanguard capital management llc | 2,222 | $3K |
| blackrock, inc. | 479 | $575 |
| sbi securities co., ltd. | 205 | $246 |
| caitong international asset management co., ltd | 3 | $4 |
| brown brothers harriman & co | 2 | $2 |
Showing top 10 of 12 institutional holders of MetaVia Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.7%
- Days to cover
- 0.3
- Shares short
- 56,743
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MTVA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MetaVia Inc.?
MetaVia Inc. (MTVA) is a clinical-stage biotechnology company developing novel therapeutics for cardiometabolic diseases, with lead programs in MASH and obesity.
What is MetaVia Inc.'s lead drug candidate?
MetaVia Inc.'s most advanced tracked candidate is da-1241 (Phase 2) for MASH and Type 2 Diabetes Mellitus.
Who is the CEO of MetaVia Inc.?
Mr. Hyung Heon Kim is the chief executive officer of MetaVia Inc. (MTVA).
Where is MetaVia Inc. headquartered?
MetaVia Inc. (MTVA) is headquartered in Cambridge, MA, United States.
What therapeutic areas does MetaVia Inc. focus on?
MetaVia Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.